Drug intelligence / Profile preview

Biohalo23

Development stage: Unknown
Lead developer: BioHalo
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Biohalo23 is an upper respiratory tract probiotic formulation developed by the Chinese company Biohalo (致煜医疗). It is designed to modulate the respiratory microbiome and enhance the host's first-line immune defense against pathogens. The product is primarily indicated for the prevention and management of recurrent respiratory tract infections and otitis media (middle ear infections), particularly in pediatric populations. Its clinical utility as an adjunct to standard medical treatment was supported by a 2024 expert consensus published in the *Chinese Journal of Rational Drug Use*, which highlighted its role in reducing infection susceptibility and improving quality of life in children. Biohalo23 has been studied in both Chinese and European clinical settings as a microbial therapy to support the upper respiratory tract microbiome.

Brand names: Biohalo23Biohalo-23Biohalo 23
Other names: 上呼吸道益生菌Biohalo23

Beyond the preview

Go deeper on Biohalo23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biohalo23.

Explore the full profile